Clinical-stage biopharmaceutical company discovering and developing small-molecule radiopharmaceuticals for precision treatment and imaging of solid tumors
Clinical-stage biopharmaceutical company discovering and developing small-molecule radiopharmaceuticals for precision treatment and imaging of solid tumors. Its platform uses AI-driven multi-omics to identify cancer-selective cell-surface targets, then pairs targeted small-molecule ligands with radioisotopes for therapeutic or diagnostic use. The company has a strategic agreement with Eli Lilly involving its GPCR-targeting radiopharmaceuticals.